ERBB3 and neoplasm: Seribantumab (MM121) is a fully human antibody that directly binds to the HER3 ECD and inhibits downstream HER3-dependent pathways via induction of HER3 receptor downregulation [131] and inhibits tumor development by blocking the PI3K-ATK pathway’s activation [131,142].